🚨 Don't miss out on our webinar this Tuesday! Register now and prepare your questions for the Q&A segment: https://bit.ly/3S7j8wU
📢 Stay informed! Recent updates from regulatory bodies highlight the critical role of the CFU assay in ensuring #hematopoietic stem and progenitor cell (HSPC) product quality. 🗓️ Join our live webinar on July 30 to learn about the CFU assay and its importance for cellular therapies: https://bit.ly/3S7j8wU
📢 Stay informed! Recent updates from regulatory bodies highlight the critical role of the CFU assay in ensuring #hematopoietic stem and progenitor cell (HSPC) product quality. 🗓️ Join our live webinar on July 30 to learn about the CFU assay and its importance for cellular therapies: https://bit.ly/3S7j8wU
Aspiring Biomanufacturing Professional | Bioinformatics & Biotechnology Specialist | Ex-Uber, Microlab, Amazon | 7+ Years in Logistics & Supply Chain Management | CASTL Elevate Biomanufacturing Trainee
Don't miss out on this webinar! ( Monday for those in Eastern Time) Stay informed on the recent updates from regulatory bodies highlighting the critical role of the colony-forming unit (CFU) assay in ensuring #hematopoietic stem and progenitor cell (HSPC) product quality. 🗓️ Join STEMCELL Technologies live webinar on July 30 (11 a.m. SGT) to learn about the CFU assay and its importance for cellular therapies: https://bit.ly/3S7j8wU The webinar will cover: 🔬 The utility of the CFU assay in medical and laboratory workflows for HSPC transplantation and therapies. 🧪 How the CFU assay assesses the impact of processing on stored units of cord blood. 🔧 Methods to standardize and improve CFU assay reproducibility across different personnel and labs. 🗓️ Date: Tuesday, 29 July 2024 🕒 Time: 11 P.M. EDT #HematopoieticStemCells #CellularTherapies #CFUAssay #STEMCELLTechnologies
📢 Stay informed! Recent updates from regulatory bodies highlight the critical role of the CFU assay in ensuring #hematopoietic stem and progenitor cell (HSPC) product quality. 🗓️ Join our live webinar on July 30 to learn about the CFU assay and its importance for cellular therapies: https://bit.ly/3S7j8wU
#SNMMI24 Abstract 3: Survival Outcomes and Dosimetric Analysis of Iomab-B (131I-apamistamab) Followed by Allogeneic Hematopoietic Cell Transplant for Patients with TP53 Mutated R/R #AML. Details: https://bit.ly/3wz5SJW #BMT #Radiotherapies
The power of lentiviral vectors lies in their ability to precisely deliver therapeutic genes into the body. Lentiviral vectors can be used to express genes in autologous, allogeneic, and iPSC-derived cell therapies, and are engineered ex vivo. Our proprietary LentiPeak™ platform helps enable this process. Learn more about how our technologies can advance your life-changing therapies here: https://lnkd.in/ed8fRD-F. #LentiviralVectors #GeneTherapy
B-Xpander™ - Unleash the Power of B Cell Expansion https://lnkd.in/d-ihTakZ B-Xpander™ is a potent enhanced Multimeric human CD40L cytokine, for B cell activation, B cell expansion (proliferation) and cell therapy applications. In-house production using a proprietary protocol and a characterized and certified CHO cell line allows the supply of the most active Multimeric human CD40L proteins in GMP-like format.
Interested in the potential of serum-free media formulations in achieving high-quality T cell cultures for the scalability and reproducibility of CAR-T cell therapies?
Our recent application note demonstrates the critical role of media and cytokine supplementation in optimizing the ex vivo expansion and functionality of T cells. The data presented also supports the potential of serum-free media formulations in achieving high-quality T cell cultures, which is crucial for the scalability and reproducibility of CAR-T cell therapies. Read the full publication here: https://ow.ly/rkuf50SwNe9 #celltherapy #cytokines #cellculturemedia #research #laboratory #cancerresearch #tcells
Discover the critical role of HLA typing in the development of both autologous and allogeneic CAR-T cell therapies. Learn how different HLA typing technologies are used to optimize CAR constructs, enhance donor-recipient matching, and support the development of universal CAR-T cells. Read the new blog post: https://lnkd.in/gG2XzxDU
Early-phase cell therapy clinical trials come with distinct bioanalytical challenges and evolving regulatory considerations. Next week, we’ll be releasing an on-demand webinar titled ‘Persistence is key: Bioanalytical Strategies for Cell Therapy Clinical Trials,’ where we navigate the challenges and complexities of designing early-phase studies for cell therapies. Presented by Caroline Beltran PhD, this webinar will cover key topics such as potency, immunogenicity, cell expansion, pharmacodynamics and long-term persistence. Register to be notified and gain instant access when the webinar becomes available next week. https://lnkd.in/eaeMrs8E #Synexa #webinar #celltherapy #clinicaltrial
Learn how digital PCR can be used in PK studies to de-risk cell therapy development: https://bit.ly/4clj5Vv Accurate measurement of vector copy number (VCN) is essential during cell therapy development. At CellCarta we use both QIAcuity’s multicolor digital PCR and Bio-Rad QX200TM digital PCR for high-quality results. #CellTherapy #DigitalPCR #Pharmacokinetics #PrecisionMedicine
#SNMMI24 presentation recap: Survival Outcomes and Dosimetric Analysis of Iomab-B Followed by Allogeneic Hematopoietic Cell Transplant for Patients with TP53 Mutated R/R #AML. Details: https://bit.ly/3Rpk8vV
